Cargando…

Guselkumab-induced vitiligo in a patient with psoriatic arthritis

Detalles Bibliográficos
Autores principales:	Martora, Fabrizio, Annunziata, Maria Carmela, Guerriero, Luigi, Battista, Teresa, Potestio, Luca, Megna, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568222/ https://www.ncbi.nlm.nih.gov/pubmed/37842149 http://dx.doi.org/10.1016/j.jdcr.2023.08.043

Ejemplares similares

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
por: Battista, Teresa, et al.
Publicado: (2023)

Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
por: Martora, Fabrizio, et al.
Publicado: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
por: Potestio, Luca, et al.
Publicado: (2023)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?
por: Martora, Fabrizio, et al.
Publicado: (2023)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

Cutaneous Eruption after SARS-CoV-2 Vaccine in Psoriatic Patient Treated with Methotrexate
por: Serena, Lembo, et al.
Publicado: (2022)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
por: Orbai, Ana-Maria, et al.
Publicado: (2023)

Herpes Zoster and COVID-19 Vaccination: A Narrative Review
por: Potestio, Luca, et al.
Publicado: (2023)

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
por: Megna, Matteo, et al.
Publicado: (2021)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
por: Chen, Yang, et al.
Publicado: (2021)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

COVID‐19 vaccination and inflammatory skin diseases
por: Martora, Fabrizio, et al.
Publicado: (2022)

JAK Inhibitors in Psoriatic Disease
por: Megna, Matteo, et al.
Publicado: (2023)

Pemphigus vulgaris and COVID‐19 vaccination: Management and treatment
por: Martora, Fabrizio, et al.
Publicado: (2022)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab
por: Megna, Matteo, et al.
Publicado: (2022)

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_38ghba83f4tr4i18hvin2fc87t